three European regions. Ann Oncol. 2012; 23:2442-2449. https://doi.org/10.1093/annonc/mdr610
PMID: 22331640

8. Stiller C.A., Trama A., Serraino D., et al S., The RARECARE Working Group Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project. European Journal of Cancer 2013; 49:684-695. https://doi.org/10.1016/j.ejca.2012.09.011 PMID: 23079473

9. Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol. 2017; 18:1022-1039. https://doi.org/10.1016/S1470-2045(17)30445-X PMID: 28687376

10. Trovik C, Bauer HCF, Styring E, Sundby Hall K, Vult Von Steyern F, et al. The Scandinavian Sarcoma Group Central Register: 6,000 patients after 25 years of monitoring of referral and treatment of extremity and trunk wall soft-tissue sarcoma. Acta Orthop. 2017; 88:341-347. https://doi.org/10.1080/17453674.2017.1293441 PMID: 28266233

11. Martin-Broto J, Hindi N, Cruz J, Martinez-Trufero J, Valverde C, De Sande LM, et al. Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS). Oncologist. 2019; 24:e338-e346. https://doi.org/10.1634/theoncologist.2018-0121 PMID: 30409793

12. Kollár A, Rothermundt C, Klenke F, Bode B, Baumhoer D, Arndt V, Feller A; NICER Working Group. Incidence, mortality, and survival trends of soft tissue and bone sarcoma in Switzerland between 1996 and 2015. Cancer Epidemiol. 2019; 63:101596. https://doi.org/10.1016/j.canep.2019.101596 PMID: 31520938

13. Ressing M, Wardelmann E, Hohenberger P, Jakob J, Kasper B, Emrich K, et al. Strengthening health data on a rare and heterogeneous disease: sarcoma incidence and histological subtypes in Germany. BMC Public Health. 2018 Feb 12; 18(1):235. https://doi.org/10.1186/s12889-018-5131-4 PMID: 29433465; PubMed Central PMCID: PMC5809940. Yang Z, Zheng R, Zhang S, Zeng H, Li H, Chen W. Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China. Cancer Biol Med. 2019; 16:565-574.

14. Bessen T, Caughey GE, Shakib S, Potter JA, Reid J, Farshid G, et al. A population-based study of soft tissue sarcoma incidence and survival in Australia: An analysis of 26,970 cases. Cancer Epidemiol. 2019; 63:101590. https://doi.org/10.1016/j.canep.2019.101590 PMID: 31520939

15. Gage MM, Nagarajan N, Ruck JM, Canner JK, Khan S, Giuliano K, et al. Sarcomas in the United States: Recent trends and a call for improved staging. Oncotarget. 2019; 10:2462-2474. https://doi.org/10.18632/oncotarget.26809 PMID: 31069009

16. Lurkin A, Ducimetière F, Vince DR, Decouvelaere AV, Cellier D, Gilly FN, et al. Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region. BMC Cancer. 2010; 10:150. https://doi.org/10.1186/1471-2407-10-150 PMID: 20403160

17. Casali PG, Bielack S, Abecassis N, et al; ESMO Guidelines Committee, PaedCan and ERN EURACAN. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29 (Supplement_4):iv79-iv95.

18. Casali PG, Abecassis N, Bauer S, et al. ESMO Guidelines Committee and EURACAN. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Supplement_4):iv68-iv78.

19. Casali PG, Abecassis N, Bauer S, et al; ESMO Guidelines Committee and EURACAN. Soft issue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Supplement_4):iv51-iv67.

20. von Mehren M, Randall RL, Benjamin RS, et al. Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016; 14:758-86. https://doi.org/10.6004/jnccn.2016.0078 PMID: 27283169

21. Dangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I. UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res. 2016;6-20. https://doi.org/10.1186/s13569-016-0046-2 PMID: 27127605

22. Perrier L, Rascle P, Morelle M, Toulmonde M, Ranchere Vince D, Le Cesne A, et al. The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group. PLoS One. 2018 Apr 5; 13 (4):e0193330 https://doi.org/10.1371/journal.pone.0193330 PMID: 29621244

23. Perrier L, Buja A, Mastrangelo G, Vecchiato A, Sandonà P, Ducimetière F, et al. Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions. BMC Health Serv Res. 2012; 12:82. https://doi.org/10.1186/1472-6963-12-82 PMID: 22455759
three European regions. Ann Oncol. 2012; 23:2442-2449. https://doi.org/10.1093/annonc/mdr610
PMID: 22331640

8. Stiller C.A., Trama A., Serraino D., et al S., The RARECARE Working Group Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project. European Journal of Cancer 2013; 49:684-695. https://doi.org/10.1016/j.ejca.2012.09.011 PMID: 23079473

9. Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol. 2017; 18:1022-1039. https://doi.org/10.1016/S1470-2045(17)30445-X PMID: 28687376

10. Trovik C, Bauer HCF, Styring E, Sundby Hall K, Vult Von Steyern F, et al. The Scandinavian Sarcoma Group Central Register: 6,000 patients after 25 years of monitoring of referral and treatment of extremity and trunk wall soft-tissue sarcoma. Acta Orthop. 2017; 88:341-347. https://doi.org/10.1080/17453674.2017.1293441 PMID: 28266233

11. Martin-Broto J, Hindi N, Cruz J, Martinez-Trufero J, Valverde C, De Sande LM, et al. Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS). Oncologist. 2019; 24:e338-e346. https://doi.org/10.1634/theoncologist.2018-0121 PMID: 30409793

12. Kollár A, Rothermundt C, Klenke F, Bode B, Baumhoer D, Arndt V, Feller A; NICER Working Group. Incidence, mortality, and survival trends of soft tissue and bone sarcoma in Switzerland between 1996 and 2015. Cancer Epidemiol. 2019; 63:101596. https://doi.org/10.1016/j.canep.2019.101596 PMID: 31520938

13. Ressing M, Wardelmann E, Hohenberger P, Jakob J, Kasper B, Emrich K, et al. Strengthening health data on a rare and heterogeneous disease: sarcoma incidence and histological subtypes in Germany. BMC Public Health. 2018 Feb 12; 18(1):235. https://doi.org/10.1186/s12889-018-5131-4 PMID: 29433465; PubMed Central PMCID: PMC5809940. Yang Z, Zheng R, Zhang S, Zeng H, Li H, Chen W. Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China. Cancer Biol Med. 2019; 16:565-574.

14. Bessen T, Caughey GE, Shakib S, Potter JA, Reid J, Farshid G, et al. A population-based study of soft tissue sarcoma incidence and survival in Australia: An analysis of 26,970 cases. Cancer Epidemiol. 2019; 63:101590. https://doi.org/10.1016/j.canep.2019.101590 PMID: 31520939

15. Gage MM, Nagarajan N, Ruck JM, Canner JK, Khan S, Giuliano K, et al. Sarcomas in the United States: Recent trends and a call for improved staging. Oncotarget. 2019; 10:2462-2474. https://doi.org/10.18632/oncotarget.26809 PMID: 31069009

16. Lurkin A, Ducimetière F, Vince DR, Decouvelaere AV, Cellier D, Gilly FN, et al. Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region. BMC Cancer. 2010; 10:150. https://doi.org/10.1186/1471-2407-10-150 PMID: 20403160

17. Casali PG, Bielack S, Abecassis N, et al; ESMO Guidelines Committee, PaedCan and ERN EURACAN. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29 (Supplement_4):iv79-iv95.

18. Casali PG, Abecassis N, Bauer S, et al. ESMO Guidelines Committee and EURACAN. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Supplement_4):iv68-iv78.

19. Casali PG, Abecassis N, Bauer S, et al; ESMO Guidelines Committee and EURACAN. Soft issue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Supplement_4):iv51-iv67.

20. von Mehren M, Randall RL, Benjamin RS, et al. Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016; 14:758-86. https://doi.org/10.6004/jnccn.2016.0078 PMID: 27283169

21. Dangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I. UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res. 2016;6-20. https://doi.org/10.1186/s13569-016-0046-2
PMID: 27127605

22. Perrier L, Rascle P, Morelle M, Toulmonde M, Ranchere Vince D, Le Cesne A, et al. The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group. PLoS One. 2018 Apr 5; 13 (4):e0193330 https://doi.org/10.1371/journal.pone.0193330 PMID: 29621244

23. Perrier L, Buja A, Mastrangelo G, Vecchiato A, Sandonà P, Ducimetière F, et al. Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions. BMC Health Serv Res. 2012; 12:82. https://doi.org/10.1186/1472-6963-12-82 PMID: 22455759
24. Blay JY, Soibinet P, Penel N, Bompas E, Duffaud F, Stoeckle E, et al. Improved survival using specialized multidisciplinary board in sarcoma patients. Ann Oncol. 2017; 28:2852–2859. https://doi.org/10.1093/annonc/mdx484 PMID: 29117335

25. Blay JY, Honoré C, Stoeckle E, Meeus P, Jafari M, Gouin F, et al. Surgery in reference centers improves survival of sarcoma patients: a nationwide study. Ann Oncol. 2019; 30:1143–1153. https://doi.org/10.1093/annonc/mdz124 PMID: 31081028

26. Sanfilippo R, Jones RL, Blay JY, et al. Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). Clin Cancer Res. 2019; 25:5295–5300. https://doi.org/10.1158/1078-0432.CCR-19-0288 PMID: 31217199

27. Frezza AM, Assi T, Lo Vullo S, et al. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer. 2020; 126:98–104. https://doi.org/10.1002/cncr.32508 PMID: 31536651

28. Demetri GD, Antonescu CR, Bjerkehagen B, et al. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol. 2020; S0923-7534(20)42297-5. https://doi.org/10.1016/j.annonc.2020.08.2232 PMID: 32891793

29. Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011; 47:2493–511. https://doi.org/10.1016/j.ejca.2011.08.008 PMID: 22033323
24. Blay JY, Soibinet P, Penel N, Bompas E, Duffaud F, Stoeckle E, et al. Improved survival using specialized multidisciplinary board in sarcoma patients. Ann Oncol. 2017; 28:2852–2859. https://doi.org/10.1093/annonc/mdx484 PMID: 29117335

25. Blay JY, Honoré C, Stoeckle E, Meeus P, Jafari M, Gouin F, et al. Surgery in reference centers improves survival of sarcoma patients: a nationwide study. Ann Oncol. 2019; 30:1143–1153. https://doi.org/10.1093/annonc/mdz124 PMID: 31081028

26. Sanfilippo R, Jones RL, Blay JY, et al. Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). Clin Cancer Res. 2019; 25:5295–5300. https://doi.org/10.1158/1078-0432.CCR-19-0288 PMID: 31217199

27. Frezza AM, Assi T, Lo Vullo S, et al. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer. 2020; 126:98–104. https://doi.org/10.1002/cncr.32508 PMID: 31536651

28. Demetri GD, Antonescu CR, Bjerkehagen B, et al. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol. 2020; S0923-7534(20)42297-5. https://doi.org/10.1016/j.annonc.2020.08.2232 PMID: 32891793

29. Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011; 47:2493–511. https://doi.org/10.1016/j.ejca.2011.08.008 PMID: 22033323